melphalan and Spinal-Cord-Diseases

melphalan has been researched along with Spinal-Cord-Diseases* in 2 studies

Other Studies

2 other study(ies) available for melphalan and Spinal-Cord-Diseases

Article	Year
Chemotherapy and radiotherapy causing radiation myelopathy: what is to blame? Clinical oncology (Royal College of Radiologists (Great Britain)), 2006, Volume: 18, Issue:1 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busulfan; Humans; Male; Melphalan; Radiation Injuries; Radiotherapy; Spinal Cord Diseases	2006
Fatal radiation myelopathy after high-dose busulfan and melphalan chemotherapy and radiotherapy for Ewing's sarcoma: a review of the literature and implications for practice. Clinical oncology (Royal College of Radiologists (Great Britain)), 2005, Volume: 17, Issue:5 Radiation myelopathy is a rare, devastating, late effect of radiotherapy to the spinal cord. Spinal cord tolerance is currently accepted as about 50 Gy in 1.8-2 Gy fractions. However, the effect of chemotherapy on cord tolerance is unclear. This issue is important, given the increasing use of chemotherapy in combination with radiotherapy. We describe the case of a 17-year-old boy with a right apical paraspinal Ewing's tumour in the neck treated with induction chemotherapy, high-dose chemotherapy (busulfan and melphalan) with peripheral stem-cell rescue and, 4 months later, radiotherapy to the primary tumour site (cervical cord received 50 Gy in 30 fractions). After a latent period of 4 months, he developed a progressive, severe and ultimately fatal radiation myelopathy, which we suggest was due to a synergistic interaction between the high-dose chemotherapy and the radiotherapy. The use of such chemotherapy regimens in Ewing's tumours should be carefully considered, particularly when radiotherapy encompassing the spinal cord is an essential component of management. Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busulfan; Combined Modality Therapy; Fatal Outcome; Humans; Male; Melphalan; Radiotherapy; Sarcoma, Ewing; Spinal Cord; Spinal Cord Diseases	2005

Article

Year

Chemotherapy and radiotherapy causing radiation myelopathy: what is to blame?

Clinical oncology (Royal College of Radiologists (Great Britain)), 2006, Volume: 18, Issue:1

Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busulfan; Humans; Male; Melphalan; Radiation Injuries; Radiotherapy; Spinal Cord Diseases

2006

Fatal radiation myelopathy after high-dose busulfan and melphalan chemotherapy and radiotherapy for Ewing's sarcoma: a review of the literature and implications for practice.

Clinical oncology (Royal College of Radiologists (Great Britain)), 2005, Volume: 17, Issue:5

Radiation myelopathy is a rare, devastating, late effect of radiotherapy to the spinal cord. Spinal cord tolerance is currently accepted as about 50 Gy in 1.8-2 Gy fractions. However, the effect of chemotherapy on cord tolerance is unclear. This issue is important, given the increasing use of chemotherapy in combination with radiotherapy. We describe the case of a 17-year-old boy with a right apical paraspinal Ewing's tumour in the neck treated with induction chemotherapy, high-dose chemotherapy (busulfan and melphalan) with peripheral stem-cell rescue and, 4 months later, radiotherapy to the primary tumour site (cervical cord received 50 Gy in 30 fractions). After a latent period of 4 months, he developed a progressive, severe and ultimately fatal radiation myelopathy, which we suggest was due to a synergistic interaction between the high-dose chemotherapy and the radiotherapy. The use of such chemotherapy regimens in Ewing's tumours should be carefully considered, particularly when radiotherapy encompassing the spinal cord is an essential component of management.

Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busulfan; Combined Modality Therapy; Fatal Outcome; Humans; Male; Melphalan; Radiotherapy; Sarcoma, Ewing; Spinal Cord; Spinal Cord Diseases

2005